 Despite the recent advances in medical and surgical treatment, heart failure resulting from ischemic cardiomyopathy ICM remains the leading cause of cardiovascular mortality. Ischemic dilated cardiomyopathyICM is defined as abnormally enlarged left ventricular LV cavity with documented poor LV function as a result of severe coronary artery disease CAD. LV remodelling which is inevitable after an infarct has been postulated to contribute largely to the poor outcome of patients with ICM, therefore prevention of LV remodelling is the goal for the treatment in patients with severe CAD. Cell therapy represents a novel therapeutic strategy for treating cardiac diseases including severe CAD and heart failure. A type of stem cells known as mesenchymal stem cellsMSCscan be isolated from bone marrow.This study aims to test the differentiation potential and therapeutic capacity of MSC from severe CAD patients after intracoronary implantation in an ischemic myocardial environment in Malaysian population. 